Nasus Pharma Ltd. (AMEX: NSRX) Stock Competitors & Peer Comparison

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, RPRX has a market cap of 27B. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while RPRX trades at $60.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas RPRX's P/E ratio is 11.59. In terms of profitability, NSRX's ROE is -1.59%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, NSRX is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check RPRX's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while CORT trades at $113.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas CORT's P/E ratio is 325.37. In terms of profitability, NSRX's ROE is -1.59%, compared to CORT's ROE of +0.08%. Regarding short-term risk, NSRX is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check CORT's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas WBA's P/E ratio is -1.64. In terms of profitability, NSRX's ROE is -1.59%, compared to WBA's ROE of -0.42%. Regarding short-term risk, NSRX is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check WBA's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, KNSA has a market cap of 6.1B. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while KNSA trades at $78.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas KNSA's P/E ratio is 88.67. In terms of profitability, NSRX's ROE is -1.59%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, NSRX is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check KNSA's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, LQDA has a market cap of 6B. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while LQDA trades at $67.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas LQDA's P/E ratio is 483.50. In terms of profitability, NSRX's ROE is -1.59%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, NSRX is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check LQDA's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, PBH has a market cap of 2.5B. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while PBH trades at $52.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas PBH's P/E ratio is 11.87. In terms of profitability, NSRX's ROE is -1.59%, compared to PBH's ROE of +0.09%. Regarding short-term risk, NSRX is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check PBH's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, LTGO has a market cap of 1.5B. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while LTGO trades at $24.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas LTGO's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to LTGO's ROE of N/A. Regarding short-term risk, NSRX is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check LTGO's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas HROWL's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, NSRX is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check HROWL's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas HROWM's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, NSRX is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check HROWM's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, HELP has a market cap of 755M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while HELP trades at $12.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas HELP's P/E ratio is -2.92. In terms of profitability, NSRX's ROE is -1.59%, compared to HELP's ROE of -0.71%. Regarding short-term risk, NSRX is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check HELP's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas SVA's P/E ratio is -5.68. In terms of profitability, NSRX's ROE is -1.59%, compared to SVA's ROE of -0.01%. Regarding short-term risk, NSRX is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check SVA's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, CUVL has a market cap of 310.6M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while CUVL trades at $6.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas CUVL's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to CUVL's ROE of N/A. Regarding short-term risk, NSRX is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check CUVL's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, CELG-RI has a market cap of 244.7M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, NSRX is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check CELG-RI's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, HITI has a market cap of 220.6M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while HITI trades at $2.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas HITI's P/E ratio is -7.36. In terms of profitability, NSRX's ROE is -1.59%, compared to HITI's ROE of -0.43%. Regarding short-term risk, NSRX is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check HITI's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas ATLN's P/E ratio is -0.68. In terms of profitability, NSRX's ROE is -1.59%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, NSRX is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check ATLN's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, CTOR has a market cap of 72.1M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while CTOR trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas CTOR's P/E ratio is -1.65. In terms of profitability, NSRX's ROE is -1.59%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, NSRX is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check CTOR's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, SDEV has a market cap of 47.8M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while SDEV trades at $0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas SDEV's P/E ratio is -0.17. In terms of profitability, NSRX's ROE is -1.59%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, NSRX is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check SDEV's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas RAD's P/E ratio is -0.05. In terms of profitability, NSRX's ROE is -1.59%, compared to RAD's ROE of +2.76%. Regarding short-term risk, NSRX is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check RAD's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas GLTO's P/E ratio is -1.78. In terms of profitability, NSRX's ROE is -1.59%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, NSRX is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check GLTO's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, SCYX has a market cap of 34M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while SCYX trades at $5.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas SCYX's P/E ratio is -1.58. In terms of profitability, NSRX's ROE is -1.59%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, NSRX is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check SCYX's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, CNSY has a market cap of 21M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while CNSY trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas CNSY's P/E ratio is -0.42. In terms of profitability, NSRX's ROE is -1.59%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, NSRX is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check CNSY's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, BFRI has a market cap of 20.4M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while BFRI trades at $1.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas BFRI's P/E ratio is -2.89. In terms of profitability, NSRX's ROE is -1.59%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, NSRX is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check BFRI's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, SCNX has a market cap of 16M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while SCNX trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas SCNX's P/E ratio is -0.16. In terms of profitability, NSRX's ROE is -1.59%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, NSRX is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check SCNX's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, BFRIW has a market cap of 14.2M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while BFRIW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, NSRX's ROE is -1.59%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, NSRX is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check BFRIW's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, COSM has a market cap of 12.2M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while COSM trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas COSM's P/E ratio is -0.30. In terms of profitability, NSRX's ROE is -1.59%, compared to COSM's ROE of -1.19%. Regarding short-term risk, NSRX is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check COSM's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas CJJD's P/E ratio is -0.46. In terms of profitability, NSRX's ROE is -1.59%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, NSRX is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check CJJD's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas SSY's P/E ratio is -2.86. In terms of profitability, NSRX's ROE is -1.59%, compared to SSY's ROE of -0.09%. Regarding short-term risk, NSRX is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check SSY's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, POM has a market cap of 6.4M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while POM trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas POM's P/E ratio is -0.19. In terms of profitability, NSRX's ROE is -1.59%, compared to POM's ROE of +0.16%. Regarding short-term risk, NSRX is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check POM's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while BGMS trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas BGMS's P/E ratio is -0.25. In terms of profitability, NSRX's ROE is -1.59%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, NSRX is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check BGMS's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, PAVS has a market cap of 4.1M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while PAVS trades at $4.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas PAVS's P/E ratio is -0.05. In terms of profitability, NSRX's ROE is -1.59%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, NSRX is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check PAVS's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas MDVL's P/E ratio is -0.05. In terms of profitability, NSRX's ROE is -1.59%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, NSRX is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check MDVL's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas ATNFW's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, NSRX is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check ATNFW's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, NSRX's ROE is -1.59%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, NSRX is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check BGMSP's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas AZNH's P/E ratio is 38.35. In terms of profitability, NSRX's ROE is -1.59%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, NSRX is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check AZNH's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, NSRX's ROE is -1.59%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, NSRX is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check LFLYW's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, PRPH has a market cap of 295.7K. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while PRPH trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas PRPH's P/E ratio is -0.01. In terms of profitability, NSRX's ROE is -1.59%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, NSRX is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check PRPH's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, CPD has a market cap of 0. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas CPD's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to CPD's ROE of N/A. Regarding short-term risk, NSRX is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CPD's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, OREX has a market cap of 0. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas OREX's P/E ratio is -0.14. In terms of profitability, NSRX's ROE is -1.59%, compared to OREX's ROE of -0.54%. Regarding short-term risk, NSRX is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check OREX's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas ESRX's P/E ratio is 10.69. In terms of profitability, NSRX's ROE is -1.59%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, NSRX is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check ESRX's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas SHPG's P/E ratio is 11.35. In terms of profitability, NSRX's ROE is -1.59%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, NSRX is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check SHPG's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, POZN has a market cap of 0. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas POZN's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to POZN's ROE of +0.61%. Regarding short-term risk, NSRX is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check POZN's competition here

Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NSRX stands at 34.9M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, NSRX is priced at $4.10 on the AMEX, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NSRX currently has a P/E ratio of -5.62, whereas IPXL's P/E ratio is -10.11. In terms of profitability, NSRX's ROE is -1.59%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, NSRX is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check IPXL's competition here